Webinar: Fully Human Antibody Therapeutics on RenMab Discovery Platform
Date: MAY 28, 2020 1:00 PM
Speaker: BENNY YANG, PHD, Chief Scientific Officer & Head of Drug Discovery of Biocytogen
About the webinar:
In vivo antibody discovery using transgenic/humanized mice is of rising importance for the antibody community as it offers a multitude of benefits over in vitro methods.
Benefits of in vivo method for antibody discovery and latest technical data including affinity and antibody repertoire analysis for RenMab™ Antibodies.
Brief communication of RenMab Mouse in the production of anti-SARS-CoV-2 antibodies as an on-going project.
Development of RenMab platform to address difficult target (such as GPCR) through “RenMab + target knockout” (Project Integrum), as well as novel fully human antibody mice for bispecific and single-domain antibodies, respectively.